If you are not happy with the results below please do another search
In the sea of content today, customers – HCPs and consumers alike – are overwhelmed with information. This content might be reaching them, but not effectively resonating and activating them to change behaviors. Cutting through this noise requires creative effectiveness that can only happen by harnessing the right data, technology and AI to drive next level audience understanding and as such, next level engagement.
Aldaia is president of H4B Chelsea. Her 20+ years in the industry includes leadership roles at Omnicom and WPP, with a dedicated focus on improving health outcomes through meaningful consumer and professional health communications.
Following the regulatory victory of Balversa in urothelial carcinoma, Johnson & Johnson on Friday continued its bladder cancer winning streak with an 82.8% complete response rate forTAR-200 in high-risk non-muscle invasive bladder cancer.
Andrew Baum, M.D. will play a vital role in advancing Pfizer’s long-term corporate strategic plan to maximize value for patients and shareholders. He will also be responsible for our portfolio analysis and prioritization functions, business development activities, strengthening our partnerships with the biotech ecosystem, and the commercial evaluation of our research pipeline.
A record 8,000 attendees are expected at this week’s 27th Annual Meeting of the American Society of Gene & Cell Therapy in Baltimore to discuss the opportunities and challenges facing the industry. Billed as the largest gathering of gene and cell therapy professionals, ASGCT 2024 starts tomorrow and will run through the end of the week, bringing together stakeholders from therapeutic developers and investors to patient advocates, policymakers and regulators.
FDA Commissioner Robert Califf has said that advisory committee meetings should focus more on discussion and be “less about the outcome,” but other agency officials recently advocated for retaining the vote on whether to approve a product under review.
The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States.
BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros.
In the dynamic realm where technology meets humanity, we are seeing a new frontier called digital twins. These AI-driven entities, also known as digital humans or synthetic clones, are reshaping the future of education, research, and training across nearly every sector, including the pharmaceutical and life sciences industries.
The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it.
